Complete clinical work-up (site and extent of tumor, stage, morphologic type etc.) Record , --
The decision to use radiotherapy as a treatment modality must be based on adequate clinical work-up including confirmation of the histological diagnosis, staging, etc. In the radiotherapy process, different steps then have to be taken successively, as illustrated in Fig. 2.1 .
The specification of volumes and doses serves three different purposes, namely:
for prescribing therapy, -for recording therapy (documentation), -for reporting therapy. Prescription of the radiation treatment includes a statement of the aim of therapy (Section 2.2), the definition of volumes (Section 2.3) and the specification of doses (Section 2.4) that are prescribed as well as other treatment parameters, e.g. , fractionation. Prescription of the treatment is a clinical decision, based on the judgement and experience of the radiation oncologist for the given type of disease and clinical situation. The prescribed dose depends on the aim of therapy (tumor eradication or palliation). However, the tolerance of surrounding normal tissues will also have to be taken into account and this could modify the prescribed dose. The prescribed dose, with acceptable dose variation, should be delivered to each defined tissue volume of interest. A provisional prescription of treatment should be performed at the time of the decision to use radiotherapy. When a standardized treatment technique is to be used (e.g., according to the department's policy, or according to a protocol), it is often possible to have a sufficient knowledge of the probable final dose distribution for this provisional prescription to remain unchanged during the planning process. However, this is not always the case, and then the prescription has to be modified during treatment planning (feedback procedure).
If the intent of therapy is changed, e.g. , from radical to palliative (Section 2.2), then it may well turn out that it is not meaningful to stay with the provisional prescription, and the final prescription may well have to be modified from the provisional one.
The radiation oncologist should have the freedom to prescribe the parameters in his / her own way, mainly using what is current practice to produce an expected clinical outcome of the treatment. The prescription should, however, always be unambiguous and comprehensible to all of the staff in the department, and it should allow for a later specification for recording and for reporting.
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Recording of parameters related to the treatment (see Appendix I, Table 1 .1.) should be possible during the whole treatment procedure, as indicated in Fig.  2.1 ., and a summary should be made in an unambiguous way.
Reporting of the treatment should be unambiguous and sufficiently detailed to fulfil the statements already given in the introduction (Section 1). The radiation oncologist and physicist have, in contrast to when prescribing, no freedom when reporting basal data on volumes and doses. Recommendations for reporting the different parameters are given in Section 3, and different aspects of these are dealt with in Appendix I.
Aim of Therapy
A. Radical Treatment of Malignant Disease. The aim of radical radiotherapy ("curative radiotherapy" ) is to decrease the number of tumor cells to a level that achieves permanent local tumor control. The volumes to be irradiated have to include any demonstrated tumor, and also volumes in which subclinical spread is expected at a given level of probability. These different volumes will often have to be irradiated to different dose levels. In the radical treatment of malignant disease, anatomical tumor limits thus mayor may not be demonstrable. When the tumor has been previously removed (e.g. , by mastectomy or hysterectomy), the remaining tissue may contain subclinical disease, the limits of which cannot be demonstrated clinically. B. Palliative Treatment of Malignant Disease. The aim of palliative radiotherapy is to decrease symptoms (e.g., pain) of the malignant disease. The palliative treatment of malignant disease may include all or only part ofthe demonstrated tumor (e.g. , irradiation of the spine for a painful deposit in a case of wide-spread metastases). C. Non-malignant Diseases. The radiotherapy of non-malignant conditions mayor may not include all of the affected tissues (e.g., irradiation of dermatoses) . The recommendations in this report are based on situation A, but are, in principle, also applicable to situations Band C.
Volumes
The process of determining the volumes for the treatment of a malignant disease consists of several distinct steps. Different volumes may be defined, often with varying concentrations of demonstrated or suspected malignant cells. Furthermore, considerations have to be given to probable changes in the spatial relationship between the volume(s) and therapy beam(s) during treatment, viz., movements of the tissues/ patient, and to possible inaccuracies in the treatment set-up.
Two volumes should be defined prior to treatment planning. These volumes are:
Gross Tumor Volume (GTV Acquisition of additional anatomical data besides the diagnostic information may be needed, and should be obtained with the patient under treatment conditions. Such further information could be CT -scans or orthogonal x-ray films in the treatment position.
The palpable or visible extent of the malignant tumor (evaluated also by different imaging techniques) constitutes the Gross Tumor Volume (GTV). Usually, depending on tumor site and diagnostic methods, this volume corresponds to the part of the disease where the malignant tumor cell concentration is at its maximum.
Next, a margin has to be added around the Gross Tumor Volume to include direct, local subclinical spread. This volume surrounding the GTV often has a high tumor cell density close to the demonstrated 2.3 Volumes ... 5 tumor with decreasing density towards the periphery. The GTV and its local margin for subclinical disease constitute a Clinical Target Volume (CTV) (e.g., CTV I).
If the tumor has been removed prior to radiotherapy, no Gross Tumor Volume can be defined.
Additional volumes which do not contain demonstrable tumor but with suspected malignant cells, may also be considered for therapy (e.g., regional lymph nodes and their volumes for subclinical spread). These volumes with only subclinical disease also constitute Clinical Target Volumes (e.g., CTV II, etc.).
The delineation of the Gross Tumor Volume and the Clinical Target Volume are based on purely anatomic-topographic and biological considerations without regard to technical factors of treatment.
For radiation treatment planning and for adequate ==4---4---1--Gross tumor volume 
Irradiated volume
Clinical Target Volume (CTV) denotes the demonstrated tumor (when present) and also volumes with suspected (subclinical) tumor (e.g., margin around the GTV, and e.g., regional lymph nodes, NO (according to the TNM-classification [VICC, 1987] ), considered to need treatment). The CTV is thus a pure anatomic· clinical concept.
Planning Target Volume (PTV) consists of the CTV(s) and a margin to account for variations in size, shape, and position relative to the treatment beam(s). The PTV is thus a geometrical concept, used to ensure that the CTV receives the prescribed dose, and it is (like the patient/tissues concerned) defined in relation to a fixed coordinate system. Note that in the example shown the magnitude of foreseen movements of the CTV is different in different directions.
Treated Volume is the volume that receives a dose that is considered important for local cure or palliation. Irradiated Volume is the volume that receives a dose that is considered important for normal tissue tolerance (other than those specifically defined for organs at risk).
... 2. Definitions of Terms and Concepts
treatment set-up, margins have to be added around the Clinical Target Volume to account for variation in size and position of tissues relative to the treatment beams, due to, e.g., patient movement, respiration, changes in size and internal position of the Clinical Target Volume and to variation in the daily set up due to technical and other factors. This volume, which takes into account both anatomical/biological factors and treatment reproducibility factors, is the Planning Target Volume (PTV).
Gross Tumor Volume (GTV)
From the origin of medical terminology the word tumor (latin tumor) was used to designate a swelling, which could be of different natures.
The Gross Tumor Volume (GTV) is the gross palpable or visible / demonstrable extent and location of malignant growth.
The GTV may consist of primary tumor, metastatic lymphadenopathy, or other metastases. The GTV corresponds usually to those parts of the malignant growth where the tumor cell density is largest. No GTV can be defined if the tumor has been removed, e.g., by previous surgery.
The shape, size, and location of the GTV may be determined by means of different diagnostic methods such as clinical examination (e.g., inspection, palpation, endoscopy), and various imaging techniques (e.g., x-ray, CT, DI, US, MRI, and radioisotope methods). The methods used to determine the GTV should meet the requirements for staging the tumor according to the clinical TNM (UICC, 1987) , and (AJCCS, 1988) , and the definition of the G"I:V is then in full agreement with the criteria used for the TNMclassification.
The GTV (primary tumor, metastatic lymphadenopathy, other metastases) may seemingly be different in size and shape, sometimes significantly, depending on what examination technique is used for evaluation (e.g., palpation versus mammography). The therapist should, in each case, therefore, indicate which methods have been used for evaluation and for definition of the GTV.
There are at least two reasons to identify the GTV. Firstly, an adequate dose must be delivered to the whole GTV in order to obtain local tumor control in radical treatments. Secondly, identification is necessary to allow for recording of tumor response in relation to the dose and its variation, and to other relevant factors.
Clinical Target Volume (CTV)
In the previous recommendations (Report 29, [ICRU 1978]), the "Target Volume" was defined to include not only the GTV but also volumes with suspected, subclinical disease, and, furthermore, it was previously also defined to include margins for expected variations in shape, size, and position of the demonstrated tumor and/or subclinical disease, as well as variations in patient set-up and beam sizes and orientation. There are reasons to differentiate between, on the one hand, considerations taking into account purely oncologic/biological factors (Clinical Target Volume [CTV]) , and, on the other hand, margins taking into account the reproducibility of different anatomical/technical factors in treatment set up (Planning Target Volume [PTV]) (see 2.3.3). A detailed analysis of the problem was given by Goitein (1985) .
Clinical experience indicates that around the GTV there is generally subclinical involvement, i.e., individual malignant cells, small cell clusters, or microextensions, which cannot be detected by the staging procedures. The volume surrounding the macroscopic tumor has usually a high tumor cell density close to the edge of the GTV with decreasing density towards the periphery of this volume (often a margin of about 1 cm). The GTV together with this surrounding volume of local subclinical involvement is now defined as a Clinical Target Volume (CTV). This CTV will usually be denoted CTV I.
The delineation of a CTV is thus based on purely anatomic-topographic and biological considerations without regard to movement of the tissues/patient or technical factors, and it should be described in anatomic-topographic terms.
Additional volumes with presumed subclinical spread (e.g., regionallymphnodes) may also be considered for therapy. They are also defined as Clinical Target Volumes, and may be designated CTV II, CTV III, etc.
The Clinical Target Volume (CTV) is a tissue volume that contains a demonstrable GTVand/or subclinical microscopic malignant disease, which has to be eliminated. This volume thus has to be treated adequately in order to achieve the aim of therapy, cure or palliation.
In external beam radiotherapy, the Clinical Target Volume (CTV) is a tissue volume that has to be irradiated to a specified dose according to a specified dose-time pattern.
If different doses are prescribed, this implies the definition of different CTVs for different dose levels. Thus, for any given situation, there is often more than one CTV. One situation can be illustrated by considering a primary tumor and its regionallymphatics separately (e.g., in breast saving procedures where the breast and regional lymphatics are separated anatomically). In other situations, the aim is to treat two CTVs to different dose levels ("boost" therapy), where the "high-dose" volume (often containing the GTV) is located inside the "low-dose" volume.
In some cases, a dose gradient over a volume may be wanted and this gradient may be either continuous or step-wise. The decision to prescribe different doselevels or dose-gradients is based on an estimate of variations in tumor cell densities in different volumes or along different lines.
In practice, the delineation of a CTV will require consideration of factors such as the local invasive capacity of the tumor and its potential to spread to, e.g., regional lymph nodes. Consideration may also need to be given to the presence of any specially radiosensitive normal tissue (Organs at Risk, Section 2.3.6) as well as to other factors such as the general condition of the patient.
If there is a change in the size, shape, and location of a CTV during treatment (e.g., shrinkage of a tumor during therapy, or the addition of further diagnostic data), there may be a need for re-planning.
It must be clearly recognized that volumes are treated, even if representations of volumes usually are given only in two dimensions, or linearly. For documentation and retrieval, it is an advantage if the different parts of the CTVs are codified according to an internationally recognized system (e.g., lCD, or SNOMED, see Section 3.2.2 and Appendix I).
The definitions of the GTV and CTV are thus entirely based on general oncologic principles, and are not limited to external beam therapy. Thus, in surgery, a safety margin is taken around the gross tumor according to clinical judgement, and this implies the same use of the Clinical Target Volume concept as in external beam therapy. Also, in brachytherapy, volumes to be irradiated are defined, and thus the concept of CTV is valid. Furthermore, the concept can be applied to other modalities, e.g., regional chemotherapy, hyperthermia, and photocoagulation.
For external beam radiotherapy, additional volumes have to be defined, as given below.
Planning Target Volume (PTV)
To ensure that all tissues included in the Clinical Target Volume receive the prescribed dose, one has, in principle, to plan to irradiate a geometrically larger volume than the CTV. Ideally, the position, shape, and size of the CTV and of the treatment beams should be related to a common fixed coordinate system in a reproducible way. However, in practice, this will not be possible to achieve, and intrafractional as well as interfractional variations in this respect may be foreseen due to a number of factors such as: ' movements of the tissues which contain the 2.3 Volumes ... 7 CTV (e.g., with respiration), as well as movements of the patient, variations in size and shape of the tissues that contain the CTV (e.g., different fillings of the bladder), variations in beam geometry characteristics (e.g., beam sizes, beam directions). This leads to the concept of the Planning Target Volume (PTV).
The Planning Target Volume is a geometrical concept, and it is defined to select appropriate beam sizes and beam arrangements, taking into consideration the net effect of all the possible geometrical variations, in order to ensure that the prescribed dose is actually absorbed in the CTV.
The PTV is related to the beam(s) through a fixed coordinate system (e.g., couch top or laser planes through a tatoo or a bony landmark).
The PTV is used for dose planning and for specification of dose. Therefore, the PTV has to be clearly indicated on the s.ections used for dose planning. The dose distribution to the PTV has to be considered to be representative of the dose to the CTV.3
Note that the definition of Planning Target Volume is identical to the previous (Report 29, [ICRU 1978]) definition of "Target Volume." The two concepts are thus synonymous.
Depending on the clinical situation (e.g., patient condition and site of the CTV) and the chosen technique, the PTV could be very similar to the CTV (e.g., in the case small skin tumors, pituitary tumor), or by contrast, much larger (e.g., lung tumors). The PTV may surpass normal anatomical borders (e.g., it may include parts of clinically unaffected bony structures), or even extend into the air (e.g., in a case of tangential irradiation of a breast).
The Planning Target Volume is thus a static, geometrical concept, used for treatment planning. The PTV does not, in fact, exactly represent defined tissues or tissue borders. Actually, the tissues contained geometrically within the PTV may not truly receive the planned dose distribution, at least not in some parts close to its border. This is due to the variation in position of the CTV within the boundaries of the PTV during a course of treatment. However, the PTV is the volume that is used for dose calculation and for specification of target dose (see Section 3).
An example of Gross Tumor Volume, Clinical Target Volume and Planning Target Volume for a patient with a carcinoma ofthe bronchus is shown in Fig. 2.3 .
When defining the PTV for a given CTV, one has to make an estimation of the overall importance of the possible variations in relation to the selected beam arrangement, considering, furthermore, anatomical location, the use of patient immobilization devices, etc. Also, consideration has to be given to the fact that most imaging techniques used for dose-planning (mainly x-ray diagnostic procedures) actually show the situation in seconds or fractions of a second, and I, , Fig.2 .:I.b. The demon5trnted tumor in the right hilar region extending into the lung tissue. but not involving the chest wall is the CT\'. and is shown by the strioted area. not the whole integrated situation during the actual treatment (= exposure time for a s ingle treatment fraction).
It is not recommended that all uncertainties due to the movements and spatial variations be added linearly because this would probably lead to too large margins, resulting in unnecessary side·effects. Some of the movements and variations previously listed could systematically deviate at the time of the irradiation compared to the planning process. Other u ncertainties may vary at random. It is desirable to have detailed estimation of all these spatial uncertainties. Fig.2.3.c . A margin is added around the GTV to include presumed local subclinical involvement around the demonstrable tumor, due to individual malignant cells, small cell clusters, or microextensions, which can not be detected clinically. This constitutes the CTV I, and is shown by the broken line.
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However, the information that can be obtained is usually limited, and they can only be estimated. If the random uncertainties are normally distributed and the systematic uncertainties are estimated by their standard deviations, the combined effect can be estimated. The total standard deviation is then the root of the square sum of random and systematic uncertainties. , Fig. 2.3 .d. There wer(l no mediustinal lymph node metastases that could be demonstrated by clinical investigations. However, the medinstinallymph nodes us well liS the medial parts of the contralateral hilar region Ur<J considered to be at high risk. and to be trcuted for subclinical disease liS CTV I I. shown by the broken line.
Treatment planning consists of the delineation of the Clinical Target Volume and the prescription of lhe Target Dose. Th is constitutes the pure medical prescri ption, which must precede the integrated pro· cess of defining a proper Plann ing Target Volume with respect to the technical factors ofthe irradiation , including select ion of beam arrangements, etc. Note that for a given CTV, t he PTV may vary sign ificantly with diffe rent beam arrangements.
A Clinical Target Volume may occasionally have to
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If Fig.2. 3.e. The patient's condition did not allow for radical therapy, and the prescribed dose is the same (and relatively low) for both CTV I and CTV II. The two CTVs will be treated with the same beams, and a re here shown joined. be represented by 2 or more Planning Target Volumes. Such special situations are illustrated in Figs. 2.4. and 3.4.
When a dose distribution in one or more anatomical sections is presented, the PTV should be clearly indicated on the diagram (represented by an area in a particular section). It is an advantage if the CTV is also shown (Figs. 2.3 .f. and II.4.). Fig. 2.3 .f. The geometrical relationship between the CTV and other relevant parts of the patient on one hand and the treatment beam(s) on the other hand should be stable and not change during or between fractions. This relation should be correlated to a fixed coordinate system related to a point in/at the patient (e.g., the sternal notch). However, in relation to the fixed coordinate system, the CTV will move, e.g., with respiration, and the patient as a whole will not be perfectly immobilized during each fraction. Furthermore, there may be minor random variations in the set up (positioning of the beams in relation to the fixed coordinate system, small variations in beam size and blockings, etc.). Therefore, treatment has to be planned for a larger volume than the CTV, and a suitable PTV (indicated by the thick solid line) is defined for treatment planning purpose and for dose recording and reporting. Note that in this example the PTV extends into healthy tissues (the chest wall). Fig. 2.4 .h. The dose distribution corresponding to the treatment described in Fig. 2.4 .a. is shown. The following isodose curves are drawn: 2.0, l.8, l.6, l.4, l.2, and l.0 Gy.
Fig. 2.4.c.
A case of advanced carcinoma of the prostate. The local tumour and the iliac nodes have to be irradiated and the rectum to be spared. Four Planning Target Volumes are identified (thick full lines and hatched areas). The bony structures of the pelvis and femora (dotted areas), the bladder (B), and the rectum (R) are represented (thin full lines). The treatment consists of a triple arc therapy with a 10 MV linear accelerator (@ = the 3 axes of rotation). .2.4.d . The dose distribution corresponding to the treatment described in Fig. 2.4 .c. The following isodose curves are drawn: 2.0, 1.8, 1.6, 1.4, 1.2, and 1.0 Gy.
Fig
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Treated Volume
Ideally, the dose should be delivered only to the PTV. However, due to limitations in radiation treatment technique, this goal cannot be achieved, and this leads to the definition ofthe Treated Volume.
The Treated Volume is the volume enclosed by an isodose surface, selected and specified by the radiation oncologist as being appropriate to achieve the purpose of treatment (e.g., tumor eradication, palliation) .
When the minimum target dose envelope is selected as appropriate, the Treated Volume may, in some cases, closely match the Planning Target Volume, but in other cases, the Treated Volume may be considerably larger than the Planning Target Volume. Examples of different Treated Volumes with different techniques for the same Planning Target Volume are given in Fig. 2 .5.
If, however, the Treated Volume turns out to be smaller, or not wholly enclosing the Planning Target Volume, then the probability of tumor control is reduced, and the treatment plan has to be reevaluated and, if necessary, even the aim of therapy may have to be reconsidered.
There are several reasons for identifying the Treated Volume. One reason is that the shape and size of the Treated Volume relative to the Planning Target Volume is an important optimization parameter. Another reason is that a recurrence within the Treated Volume but outside the Planning Target Volume may be considered to be a " true," " in-field" recurrence due to inadequate dose and not a "marginal" recurrence due to inadequate volume.
Irradiated Volume
The Irradiated Volume is that tissue volume which receives a dose that is considered significant in relation to normal tissue tolerance.
The Irradiated Volume depends on the treatment technique used. The comparison of the Treated Volume and the Irradiated Volume for different beam arrangements can be used as part of the optimization procedure as illustrated in Fig. 2.5 .
If the Irradiated Volume is reported, the significant dose level must be expressed either in absolute values or relative to the specified dose to the PTV.
Organs At Risk
Organs at risk are normal tissues whose radiation sensitivity may significantly influence treatment planning and/or prescribed dose.
As is the case when defining the Planning Target Volume, any possible movement of the organ at risk during treatment, as well as uncertainties in the set up during the whole treatment course, must be considered.
Estimations of dose limits for normal tissues under different conditions have been tabulated by, e.g., Rubin (1975) , and further elaborated by Brahme et al. (1988) . Organs at risk may be divided into three different classes:
Class I organs: Radiation lesions are fatal or result in severe morbidity. Class II organs: Radiation lesions result in moderate to mild morbidity. Class III organs: Radiation lesions are mild, transient, and reversible, or result in no significant morbidity.
Absorbed Dose Distribution
The prescription of radiation treatment includes a definition of the aim of therapy and volumes to be considered, as described in Sections 2.2. and 2.3., and also a prescription of dose and fractionation.
A provisional dose prescription is usually made at the same time as the decision to use radiotherapy is made and the volumes to be considered are specified. When a standardized treatment technique is used (e.g., in a protocol), it is often possible, at the time of prescription, to have sufficient knowledge of the final dose distribution that there is no need to change the prescription due to factors that may emerge during dose planning. However, in non-standard individualized treatments, it may not be possible to achieve the prescribed doses in the selected volumes. This may be due, for instance, to high dose to organs at risk. The final dose prescription will then have to be modified from the provisional one.
Different concepts needed for reporting are defined below. Recommendations for reporting are given in Section 3.
Dose Variation in the Planning Target Volume
When the dose to a given volume has been prescribed, then the corresponding delivered dose should be as homogeneous as possible. Indeed, due to the steep slopes of the dose-effect-relationships for tumor Fig. 2.6 .a. Section at the level of Th V in a case of mammary carcinoma. The Planning Target Volume is indicated by the dotted area. Note that it extends slightly outside the surface of the skin over the breast in order to safeguard against variations in the position of the breast due to breathing and beam positioning variations.
Tangential irradiation using two opposed equally weighted 6 MV photon beams. The isodose distribution has been normalized to the dose midway between the beam entrances and on the central axes of the beams.
Area, cm 2
Dose, % Fig. 2.6 .h. Dose-area histograms for the same patient as in Fig. 2.6 control, the outcome of treatment cannot be related to dose if there is too large a dose heterogeneity. Furthermore, any comparison between different patient series becomes difficult, or even impossible. However, even if a perfectly homogeneous dose distribution is, in principle, desirable, some heterogeneity has to be accepted due to obvious technical reasons. Thus, when prescribing the treatment, one has to forsee a certain degree of heterogeneity, which today in the best technical and clinical conditions should be kept within +7% and -5% of prescribed dose (Wittkamper et al., 1987 , Brahme et al., 1988 , Mijnheer et al., 1987 . If such a degree of homogeneity cannot be achieved, it is the responsibility of the radiation oncologist to decide whether this can be accepted or not. In fact, in some cases, a higher dose may be found in a part of the PTV where the highest malignant cell concentration may be expected, especially within the GTV, and such a situation may even be of advantage. In such cases, the different dose levels in different volumes should also be reported.
For palliative treatments, and for subclinical disease, a more heterogeneous dose distribution can more often be accepted than for radical treatments.
Representation of a Spatial Dose Distribution
It must always be borne in mind that radiotherapy is concerned with volumes. Patients have a threedimensional shape, and so do Gross Tumor Volumes, Clinical Target Volumes, Planning Target Volumes, Organs at Risk, and tissue heterogeneities.
Thus, when evaluating a dose distribution, the variation within a defined volume must be taken into account. Modern dose-planning systems are based on CT cross-sectional images of the patient and should have the capacity of handling fully three-dimensional topographic patient data as well as performing a fully three-dimensional dose calculation. Methods of presenting results of calculation have been reviewed in Report 42 (ICRU 1987) , and further developments in the field are expected.
A full three-dimensional dose distribution can only be inspected and visually evaluated on the screen of the graphic's display unit. For the hard-copy documentation of an isodose distribution, only two-dimensional sections are meaningful in daily routine. For practical reasons, only a limited number of sections are used. These sections should be chosen in such a way that they illustrate as closely as possible the GTV, CTV, PTV, and organs at risk, and other structures of importance (e.g., bony landmarks). For this purpose, a series of parallel transverse planes or orthogonal planes or other presentations may be used. Usually, at least a plane through the centre of the Clinical Target Volume or Planning Target Volume is used, but often, several sections are necessary in order to display the full topography and dose distribution.
In some situations, only one section may be used for dose planning (Fig. 2.6.a.) . In doing so, one is forced to assume that all structures through which the section passes have a cylindrical shape. This assumption is, in most cases, an over-simplification and should be used with great care (Fig. 2.7.) .
Regardless of what type of section is used, the extreme outlines of the CTV, organs at risk, the tissue heterogeneities and anatomical reference points in the corresponding three-dimensional slice should be projected onto the section. The section then contains all the relevant information for the whole slice.
The isodose lines should be drawn according to given recommendations (Report 42 [ICRU, 1987] ).
In many situations, the practice is to evaluate the dose-distribution only unidimensionally, e.g., along the coinciding central axes of two opposing beams (Fig. 2.8.) , or at points on a single central axis at given depths (Fig. 2.9.) . Such procedures require, however, that a full treatment plan be worked out for reference purposes, and that the actual estimations only aim at verifying if any substantial deviations from the reference plan exist in the actual patient.
The proliferation of computers for treatment planning purposes also allows for alternative ways of presenting dose variations as histograms. This usually means displaying the dose as a distribution-function or frequency-function over a specified volume (area) (dose-volume/area histogram) ( Fig. 2.6.b.) . In addition, different single values of dose are easily obtained.
The following definitions of dose (Sections 2.4.3.-2.4.8) apply to dose calculations in a volume. When calculated in a section, they are clinically relevant only if they can be assumed to represent the entire three-dimensional situation.
Maximum Dose (Dmax)
One can identify the maximum dose within the PTV, and the maximum dose at tissues outside the PTV (e.g., at Organs at Risk [2.3.6]), or Hot Spots (2.4.8).
The maximum dose to normal tissues is of importance for limiting and for evaluating side-effects of treatment. However, a significant tissue volume must be irradiated for the dose level to be reported as 
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Beam # 1 The beam weight and corresponding total peak absorbed dose for each beam can be read from the two nomograms for different distances between the beam entrances (D) and for different beam energies.
The resulting dose distribution along the central axis is also shown. The case illustrates a quite complex situation (more than one prescribed dose, and unequally weighted beams), where, with a detailed analysis of the procedure as a basis, the routine work can be done in a greatly simplified but nevertheless standardized way. Treatment with a single 60CO gamma beam at SSD 80 cm of a patient with painful vertebral metastases (patient prone, level L III). The beam size was selected to allow for patient movement during treatment due to pain. Normalization at peak absorbed dose in the central beam ( = 100%).
For specification, the doses at the following points along the central beam axis were considered: 1. The dose at the most dorsal part of the spinal process of the vertebral body (= 98%). 2. The dose at the ventral surface of the vertebral body (= 65%). 3. The dose in the geometrical center of the whole vertebra (= midway between points 1 and 2) (= 81%). 4. The dose centrally in the vertebral body proper (= 73%). 5. The dose at the dorsal surface of the spinal cord (= 85%).
For reporting purposes, the dose at point 3 was not considered adequate, since this point is not within the proper bony structures. Instead, the dose at point 4 was selected as ICRU Reference Dose. This dose was in a position where the bone destruction was most obvious. This dose, together with the dose at point 1 and point 2, represent the Target Dose specified for reporting (= 73%, variation 98%-65% of peak absorbed dose). The dose to the organ at risk (spinal cord) is 85%.
The figure illustrates a common clinical situation. Even when no isodose distribution is available, it is possible to state within certain restrictions the PTV dose at an ICRU Reference Point and the dose variation as well as the dose to organs at risk. maximum. For three-dimensional computation, a volume is considered clinically meaningful if its minimum diameter exceeds 15 mm. A smaller volume is, in most cases, not relevant to normal tissue tolerance for large organs such as lung, liver, kidney, skin, etc. However, when other smaller organs are at risk, a dimension smaller than 15 mm has to be considered (e.g., eye, optical nerve, larynx, etc.).
The Maximum Dose to the PTV, with the areal volume restriction described above, has to be taken into account for evaluating the homogeneity of the dose distribution (part of the optimization criteria).
When the maximum dose outside the PTV exceeds the prescribed dose, then a "hot spot" can be identified (see 2.4.8). (D min ) The minimum dose is the smallest dose in a defined volume.
Minimum Dose
In contrast to the situation with the maximum absorbed dose (see 2.4.3), no volume limit is recommended when reporting minimum dose.
The Minimum Planning Target Dose is the lowest dose in the Planning Target Volume.
Average Dose (Daverage)4
The determination of the average, the median and modal doses is based on the calculation of the dose at each one of a large number of discrete points (lattice points), uniformly distributed in the volume in question.
The Average Dose is the average of the dose values in these lattice points and can be' expressed by the 4 In this report, the term average refers to the mathematical mean. The reason for using the term average instead of mean is to avoid confusion with " min." used as an abbreviation for minimum.
equation:
1 Daverage = N ~ Dij,k where N is the number of lattice points, i is the column index in this lattice, j is the row index, k is the level index, and Di j ,k is the dose at the lattice point ij,k located inside the volume V. (Dmedian) The Median Dose is the central value of the doses at all lattice points, when arranged according to magnitude. (D moda1 ) The Modal Dose is the dose that occurs most frequently at lattice points in the volume concerned. There may be more than one modal dose value, which then makes this concept useless for reporting purpose.
Median Dose
Modal Dose
NB: In order to determine the values of D average, Dmedian, and D modaJ , a complete computer-based dose distribution is required. This limits the universal use of these concepts.
Hot Spots
In many situations, tissues outside the Planning Target Volume will receive a relatively large absorbed dose.
A Hot Spot represents a volume outside the PTV which receives a dose larger than 100% of the specified PTV Dose.
As for the general rule about maximum dose (2.4.3.), a hot spot is, in general, considered significant only if the minimum diameter exceeds 15 mm. Ifit occurs in a small organ (e.g., the eye, optic nerve, larynx), a dimension smaller than 15 mm has to be considered.
